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Clinical Significance of Epidermal Growth Factor Receptors
in Non-small Cell Lung Cancer and a Prognostic Role for
HER2 Gene Copy Number in Female Patients
Samer Al-Saad, MD, PhD,*† Khalid Al-Shibli, MD, PhD,*‡ Tom Donnem, MD, PhD,§
Sigve Andersen, MD,§ Roy M. Bremnes, MD,§ and Lill-Tove Busund, MD, PhD*†
Introduction: To compare the efficacy of silver in situ hybridization
(SISH) and immunohistochemistry (IHC) in detecting HER2 alter-
ations and to investigate the prevalence and prognostic significance
of Erb family members in non-small cell lung cancer (NSCLC).
Methods: Stage I to IIIA tumors from 335 patients with NSCLC
were immunohistochemically tested for protein expression of all Erb
family members. Membranous HER2 expression was compared
with its gene copy number by SISH in paraffin-embedded, formalin-
fixed material. Correlations were made with clinicopathological
variables.
Results: Synchronous high immunohistochemical expression of all
Erb family members was seen in 8% of tumor samples. There was
a significant correlation between the HER2 gene copy number and
HER2 protein expression (p  0.003). High nuclear HER3 expres-
sion correlated significantly with high HER2 gene copy numbers
(p  0.015). In univariate analyses, high HER2 gene copy number
was a highly significant negative prognostic indicator for disease-
specific survival in women (p  0.005), whereas it did not show
prognostic influence in men (p  0.9). Neither polysomy of chro-
mosome 17 nor the IHC expression of Erb family member proteins
as singles or pairs correlated significantly with survival. In the
multivariate analysis, high HER2 gene copy number in tumor
epithelial cells (p  0.03) was an independent prognostic factor for
disease-specific survival in female patients.
Conclusions: IHC does not consistently identify patients likely to
have a poor prognosis, whereas SISH provides superior prognostic
information for female patients with NSCLC. High HER2 gene copy
number in tumor epithelial cells is an independent predictor of
inferior survival in female patients with primary NSCLC.
Key Words: Erb family members, HER2, SISH, Prognosis, Tissue
microarray, NSCLC.
(J Thorac Oncol. 2010;5: 1536–1543)
Molecular factors are gaining ground as prognosticatorsand as useful therapeutic targets against lung carci-
noma, the malignancy with the highest mortality.1 In lung
cancer, the tyrosine kinase Erb family receptors are of great
clinical research interest.2–4
The human epidermal growth factor receptor (Erb)
family consists of four membranous tyrosine kinases (EGFR,
HER2, HER3, and HER4) that differ in ligand specificity.5,6
The binding to ligands elicits their homo- or heterodimeriza-
tion and kinase domain activation initiating cascades of
cytoplasmic and nuclear mitogenic pathways including the
RAS-MAP and PI3K-Akt pathways, which lead to gene
activation and cell proliferation (Figure 1).7 HER1 (EGFR)
binds to different ligands (e.g., TGF- and amphiregulin).8
Although there are no known ligands for HER2,9 evidence
indicates that isomorphs of the new differentiation factor
(neuregulins) function as ligands for both HER3 and HER4.8
It has been proposed that HER3 lacks intrinsic kinase activity
as a single protein but can transduce signals after het-
erodimerization.10,11 Nuclear detection of HER3 (HER3n)
has been reported in prostate cancer cells12 and in colorectal
cancer cells.13 Nuclear translocation of membranous HER3,
allowing this protein to play a role as a transcription (co)fac-
tor, could explain this result.
Specific mutations in the tyrosine kinase region of the
EGFR gene, which occur most frequently in subsets of lung
adenocarcinomas in female, Asian, and/or nonsmoker popu-
lations,14,15 may identify patients with NSCLC with a good
treatment response to tyrosine kinase inhibitors.15–18
Regarding Erb family members as potential therapeutic
targets, we conducted a unique study investigating the prev-
alence and prognostic role of these proteins in NSCLC as
single proteins and as pairs. We compared the expression of
HER2 as detected by immunohistochemistry (IHC) with its
gene amplification by means of silver in situ hybridization
(SISH) stratified for clinical variables. We further studied the
nuclear and cytoplasmic expression of HER3 and its prog-
nostic significance. Finally, we investigated the correlation
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between polysomy of chromosome 17, the chromosome on
which the HER2 gene is located, and disease-specific survival
(DSS) in patients with NSCLC.
PATIENTS AND METHODS
Patients and Clinical Samples
Formalin-fixed, paraffin-embedded primary tumor tis-
sues from 371 anonymized NSCLC patients with stage I to
IIIA cancer19 at the University Hospital of North Norway and
Nordland Central Hospital from 1990 to 2004 were included
in the study. Of these 371 patients, 36 were excluded because
of the following reasons: (i) radiotherapy or chemotherapy
before surgery (n  10); (ii) other malignancy within 5 years
before the NSCLC diagnosis (n  13); or (iii) inadequate
paraffin-embedded fixed tissue blocks (n  13). The median
follow-up period was 86 months (range, 48–216). Complete
demographic and clinical data were collected retrospectively.
The last patient update was November 30, 2008. Tumors
were staged according to the TNM classification of the
International Union Against Cancer and were histologically
subtyped and graded according to the World Health Organi-
zation criteria20 by two independent pathologists at the time
of diagnosis, according to in-house regulations at University
Hospital of North Norway.
Tissue Microarray Construction
All lung cancer cases were histologically reviewed by
two pathologists (S.A.-S. and K.A.-S.). The most represen-
tative areas of viable invasive carcinoma tissues were care-
fully selected and marked on the hematoxylin and eosin (HE)
slides and were sampled for the tissue microarray construc-
tion (TMA) blocks. The TMAs were assembled using a
tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD). The detailed methodology has been previously
reported.21
Immunohistochemistry and Silver In Situ
Hybridization
Immunohistochemistry
The applied antibodies have been previously subjected
to in-house validation by the manufacturer for IHC analysis
of paraffin-embedded material. The antibodies used in the
study were as follows: Phospho-EGF Receptor/EGFR (1:250;
rabbit monoclonal, clone 53A5; #4407; Cell Signaling Tech-
nology, Danvers, MA); HER2/neu (prediluted by the manu-
facturer; rabbit monoclonal, clone 4B5; #790-100; Ventana
Medical Systems, Illkirch, France); Nuclear nonphosphory-
lated HER3 receptor (Her3n; 1:250; mouse monoclonal,
clone RTJ2; #NB100-2691; Novus Biologicals, Littleton,
CO); Phospho-HER3/HER3 (1:250; rabbit monoclonal, clone
21D3; #4791; Cell Signaling Technology); HER4 (1:50;
rabbit polyclonal, #RB-9045-R7; Thermo Fisher Scientific
Anatomic Pathology, Fremont, CA). The detailed methodol-
ogy has been previously published.21
Silver In Situ hybridization
Automated SISH was performed on a Ventana Bench-
mark XT, according to the protocols of the manufacturer for
the INFORMHER2 DNA (Ventana Medical Systems,
Illkirch, France) and chromosome 17 probes. The applied
antibodies have been previously subjected to in-house vali-
dation by the manufacturer for detection of the HER2 gene
(HER2sish) and chromosome 17 in paraffin-embedded mate-
rial. The antibodies used for SISH staining were as follows:
HER2 DNA probe (prediluted by the manufacturer; antirab-
bit, ref: 780-4332; #05273439001; Ventana Medical Systems,
FIGURE 1. Simplified schematic illustra-
tion of Erb family members transducing
signals to different oncogenes. *Pre-
sumed nuclear translocation of membra-
nous HER3.
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Illkirch, France) and chromosome 17 probe (prediluted by the
manufacturer; antirabbit, ref: 780-4331; #05273412001; Ven-
tana Medical Systems, Illkirch, France). Sections were depar-
affinized with xylene and rehydrated with ethanol. The
probes were labeled with dinitrophenol and visualized using
the rabbit anti-dinitrophenol primary antibody and the Ultra-
view SISH Detection Kit. Both the HER2 DNA and the
chromosome 17 probes were denatured at 95°C for 12 min-
utes, and hybridization was performed at 52°C for 8 hours.
The final reaction product was black metallic silver, which
was produced by the sequential addition of silver acetate,
hydroquinone, and hydrogen peroxide to the peroxidase-
conjugated goat antirabbit antibody from the detection kit.
The metallic silver was deposited in the nuclei, and a single
copy of the HER2 gene or chromosome 17 was seen as a
discrete black dot. The slides were then counterstained with
hematoxylin for interpretation by light microscopy. For each
antibody, including negative controls, all TMA stains were
performed in a single experiment. HER2 gene status was
detectable on one slide and chromosome 17 probe was
detectable on a matched slide, which allowed the HER2 gene
status to be investigated in the context of its chromosomal
state using standard light microscopy. Two discrete black
dots were observed in the nuclei of cells with normal HER2
gene copy numbers (nonmalignant cells served as internal
positive controls for staining). Small or large clusters of black
dots were seen in cells with multiple HER2 gene copies,
representing HER2 gene-amplified cells. More than two dis-
crete black dots were seen in the nuclei of cells with abnormal
numbers of chromosome 17, indicating polysomy.
Scoring of IHC and SISH
HER2 (membranous staining), HER2sish, and chromo-
some17 (black dots) each has uniform guidelines that were
strictly followed for the interpretation of staining.22 HER4
showed membranous staining similar to HER2 staining, and
thus the same scoring system was applied (Figure 2). Even
though these guidelines were developed for breast cancer
testing, we found similar staining results for NSCLC biop-
sies. Evaluation of HER2sish is reported in breast cancer as
the ratio of the average number of HER2 gene copies to the
average number of chromosome 17 copies (HER2:chr17)
per cell. Because no clear guidelines have been established
for measuring HER2 gene amplification in NSCLC, we
also sought to determine whether the number of HER2
gene copies detected by SISH (i.e., the number of black
dots observed in the nuclei of tumor cells in the HER2sish
assay) would add prognostic significance beyond that es-
tablished by the HER2/chr17 ratio. The number of gene
copies was counted according to the manufacturer’s proto-
cols for INFORMHER2 DNA. Briefly, a discrete dot was
counted as a single copy of HER2sish or chromosome 17.
Some nuclei showed multiple discrete copies. Clusters of dots
representing many copies of the HER2 gene were also appar-
ent; a small cluster of multiple signals was counted as six
copies and a large cluster was counted as 12 copies.
Staining for EGFR resulted in cytoplasmic staining,
whereas HER3 showed both cytoplasmic and nuclear staining
(Figure 2). Tissue sections for these two markers were scored
semiquantitatively for staining intensity in tumor epithelial
cells as follows: 0  negative; 1  weak; 2  intermediate;
and 3  strong. Staining for HER3n resulted in nuclear
staining with only weak cytoplasmic staining. Nuclear stain-
ing of HER3n was evaluated by taking into account both the
intensity and the density of nuclear staining. Density was
scored according to the following system: 1  less than 25%
positive nuclei in tumor cells, 2  between 25% and 50%
positive nuclei, and 3  more than 50% positive nuclei.
Nuclear staining intensity was scored according to the fol-
lowing scale: 1  weak, 2  intermediate, and 3  strong.
The mean score of nuclear staining intensity and density was
used before categorizing samples into low and high expres-
sion groups. All samples were anonymized and indepen-
FIGURE 2. Expression of Erb family members in NSCLC tis-
sues. Every row represents one single tumor, stained for dif-
ferent markers. 1, high expression; 2, low expression; 3,
normal expression (magnification 400). First row, a tumor
with high HER2 IHC expression with high HER2 gene copy
number and a normal chromosome 17 count. Second row,
a tumor with negative HER2 IHC expression with high HER2
gene copy number and a normal chromosome 17 count. Third
row, a tumor with negative HER2 IHC expression with high
HER2 gene copy number and high chromosome 17 count.
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dently scored by two pathologists. In the event of disagree-
ment, the slides were re-examined and a consensus was
reached by the observers. When assessing one variable for a
given core, the observers were blinded to the scores of the
other variables and to the outcome. The reproducibility of
the IHC evaluation in randomly selected specimens is high.
The interobserver agreement was examined with respect to
IHC scoring in 100 consecutive tumor epithelial cell cores
and tumor stroma cores stained with two rabbit polyclonal
markers: vascular endothelial growth factor-C and vascular
endothelial growth factor receptor-3.23 The average of the
mean correlation coefficient (r) for both markers was 0.95
(range, 0.93–0.98). Evaluation of simultaneous protein ex-
pression of EGFR, HER2, HER3, and HER4 was performed
by summing their intensity scores (0–3), and the mean score
was used before categorizing samples into low and high
expression groups. The same procedure was performed for all
possible receptor pairs that would occur as heterodimers.
Statistical Methods
Statistical analyses were carried out using the SPSS sta-
tistical package (Chicago, IL), version 16. The 2 test and
Fisher’s exact test were used to examine the association be-
tween molecular marker expression (for both IHC and SISH)
and various clinicopathological parameters. Univariate anal-
yses were done using the Kaplan-Meier method, and statis-
tical significance between survival curves was assessed by the
log-rank test. DSS was determined from the date of surgery to
the time of lung cancer death. Multivariate analysis was
carried out using the Cox Proportional Hazards Model. Only
variables of statistical significance from the univariate anal-
yses were entered into the Cox regression analysis. The
probabilities for stepwise entry and removal were set at 0.05
and 0.1, respectively. The prevalence of markers in tumor
tissue and normal lung tissue was assessed, and the corre-
lation between these values was calculated using Spear-
man’s test. The mean score value for all markers was used
as a cutoff point before categorization into low and high
expression groups.
Ethical Clearance
The Norwegian Data Inspection Board and the Re-
gional Committee for Research Ethics approved this study.
RESULTS
Patient Data
Demographic, clinical, and histopathologic variables
are presented in Table 1. The median age was 67 years
(range, 28–85 years), and 75% of the patients were men. The
patient population of 335 cases represented the four major
subtypes of NSCLC, with 191 squamous cell carcinomas, 95
adenocarcinomas, 31 large-cell carcinomas, and 18 bronchi-
oloalveolar carcinomas. Because of nodal metastases or non-
radical surgical margins, 55 patients (16%) received postop-
erative radiotherapy.
Expression of Epidermal Growth Factor
Receptors and the Correlations among the
Expression Levels
Of 335 cases, 313 were immunohistochemically evalu-
able for the expression of all Erb family members, including
nuclear HER3 (HER3n), whereas 275 (209 men and 66
women) were evaluable by HER2sish analysis. We found
overexpression of EGFR, HER2, HER3, HER3n, HER4, and
HER2sish in 41, 38, 34, 38, 39, and 38% of valid tumor
samples, respectively. Polysomy was seen in 14% of valid
cases. Synchronous high immunohistochemical expression
for all Erb family members, excluding HER3n, was seen in
about 8% (24 of 315 valid cases) of all tumors samples,
whereas synchronous low immunohistochemical cytoplasmic
expression was seen in 25% (77 of 315 valid cases). Preva-
lence of investigated factors is shown in Table 2.
Epidermal growth factor receptors did not correlate
with gender, histologic subtypes, WHO performance status,
or vascular infiltration. Overexpression of EGFR correlated
positively with the expression of HER3 (p 0.0001), HER3n
(p 0.0001), and HER4 (p 0.0001). A significantly higher
expression of EGFR was noted in patients who were smokers
or former smokers (p  0.028) when compared with non-
smokers. Membranous HER2 overexpression correlated sig-
nificantly with higher HER2 gene copy number (p  0.003).
Overexpression of HER3n correlated significantly with the
expression of cytoplasmic HER3 (p  0.0001) and HER4
(p  0.0001) and with higher HER2 copy numbers (p 
0.015). In addition, a higher nuclear HER3 expression was
seen in patients with polysomy of chromosome 17 (p 
0.003). Cytoplasmic HER3 expression correlated positively
with HER4 expression (p  0.0001) and with a high number
of HER2 gene copies (p  0.034). HER4 expression corre-
lated positively with tumor status (T stage, p  0.028). A
high HER2 gene copy number correlated positively with
nodal status (p  0.046). In 27% (28/105) of all patients with
a high HER2 gene copy number, simultaneous polysomy of
chromosome 17 was observed. The mean number of chro-
mosome 17 copies among all patients was 1.9, and for HER2
gene copies was 2.7 copies per cell; these values were both
regarded as cutoff points for categorizing patients into low-
and high-expression groups. There were 25 valid female
patients with high HER2 gene copy number (10 with squa-
mous carcinoma, 12 adenocarcinoma, 1 bronchioloalveolar
carcinoma, and 1 large cell carcinoma), 96% (24 of 25) were
smokers or previous smokers.
Synchronous protein overexpression (0.4; mean
value) and high HER2 gene copy number (2.7; mean value)
were present in 52 cases (19% of samples); 13 of these cases
were female patients (16% of the valid female population).
Only 10 of 321 valid cases (3.1%) showed IHC 3 according
to the HercepTest. Polysomy of chromosome 17 was ob-
served in 14% of tumor samples with a significantly negative
correlation to tumor differentiation (p  0.023).
Univariate Analysis
Gender-stratified HER2 gene copy number in tumor
epithelial cells is presented in Table 3. WHO performance
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status, tumor differentiation, surgical procedure, pathologic
stage, tumor status, nodal status, and vascular infiltration
were all significant prognostic clinical variables for the total
patient population (Table 1). Applying the criteria for breast
cancer, we found no prognostic significance for the
HER2sish/chrom17sish ratio in NSCLC (p  0.6) in the total
study population. There was no prognostic significance
among men (p  0.9) for a high HER2 gene copy number of
TABLE 1. Prognostic Clinicopathologic Variables as Predictors for Disease-Specific Survival in 335 Patients
with NSCLC (Univariate Analyses; Log-Rank Test)
Characteristic Patients, n Patients, % Median Survival, mo 5-Year Survival, % p
Age
65 yr 156 47 83 55 0.34
65 yr 179 53 NR 60
Sex
Female 82 25 190 63 0.20
Male 253 75 83 56
Smoking
Never 15 5 19 43 0.23
Current 215 64 NR 60
Former 105 31 71 54
Performance status
ECOG 0 197 59 NR 63 0.013
ECOG 1 120 36 64 52
ECOG 2 18 5 25 33
Weight loss
10% 303 90 127 58 0.71
10% 32 10 98 57
Histology
SCC 191 57 NR 66 0.08
AC including BAC 113 34 54 45
LCC 31 9 98 56
Differentiation
Poor 138 41 47 47 0.001
Moderate 144 43 190 64
Well 53 16 NR 68
Surgical procedure
Lobectomy  wedgea 243 73 190 61 0.004
Pneumonectomy 92 27 37 47
Pathological stage
I 212 63 190 69 0.001
II 91 27 41 43
IIIa 32 10 18 19
Tumor status
1 90 27 190 75 0.002
2 218 65 74 53
3 27 8 47 35
Nodal status
0 232 69 190 66 0.001
1 76 23 35 43
2 27 8 18 18
Surgical margins
Free 307 92 190 58 0.29
Not free 28 8 47 47
Vascular infiltration
No 284 85 190 58 0.001
Yes 51 15 27 32
a Wedge, n  10.
SCC, squamous cell carcinoma; AC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; LCC, large-cell carcinoma; NR, not reached; ECOG, Eastern
cooperative oncology group; NSCLC, non-small cell lung cancer.
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more than 2.7, whereas in women, a higher number of gene
copies showed a highly significant negative prognostic effect
(p  0.005; Table 3 and Figure 3). There was no significant
correlation between DSS and tumor epithelial cell expression
of EGFR (p 0.9), HER2 (p 0.2), cytoplasmic HER3 (p
0.8), nuclear HER3n (p  0.3), or HER4 (p  0.6), or
between DSS and polysomy (p  0.4). Neither overexpres-
sion of prognostic pairs nor synchronous overexpression of
all Erb family members added prognostic significance. In the
female patient population, nodal status (p  0.003) was a
significant prognostic variable, whereas both WHO perfor-
mance status (p 0.068) and tumor status (p 0.15) showed
a tendency toward prognostic significance.
Multivariate Cox Proportional Hazards Analysis
Significant clinicopathological and molecular variables
from the univariate analyses were entered into the multivar-
iate analysis. The results are presented in Table 4. In women,
a high HER2 gene copy number (p  0.03) and an advanced
nodal status (p  0.003) were both significant, independent
unfavorable indicators.
DISCUSSION
Our study was designed to clarify the role of Erb family
members in the pathogenesis of NSCLC. In addition to IHC,
we used SISH to evaluate HER2 gene copy number and
compared the recently described nuclear expression of
HER3n with its cytoplasmic expression.
FIGURE 3. Gender-stratified dis-
ease-specific survival curves for pa-
tients according to HER2 gene
copy number.
TABLE 2. Prevalence of Markers Investigated in the Study
Factor Valid Cases
High Expression Low Expression
Cases Valid (%) Cases Valid (%)
EGFR 324 133 41 191 59
HER2 321 121 38 200 62
HER3 322 109 34 213 66
HER3n 326 125 38 201 62
HER4 327 127 39 200 61
HER2sish 275 105 38 170 62
Chromosome 17 301 42 14 259 86
TABLE 3. Silver In Situ Hybridization in Women and Men
as a Predictor of Disease-Specific Survival in 335 Patients









Low 41 (62) 190 74
High 25 (38) 47 39
HER2sish (men) 0.9
Low 129 (62) 98 58




Low 170 (51) 190 62
High 105 (31) 71 52
Missing 60 (18)
NSCLC, non-small cell lung cancer.
TABLE 4. Results of Cox Regression Analysis in Women
Summarizing Significant Independent Prognostic Factors for
Disease-Specific Survival






1 1.60 0.49–5.24 0.43
2 3.90 1.61–9.46 0.003
a Overall significance as a prognostic factor.
CI, confidence interval.
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In the female patient population, independent of other
clinicopathological variables, a high HER2 gene copy num-
ber was a highly significant negative prognosticator, as de-
termined by SISH. A similar correlation was not found in the
male patient population.
There was no significant prognostic correlation of EGFR,
HER2, HER3, or HER4 investigated by IHC as single markers,
as pairs or in combination. Dysfunction in the transcriptional or
posttranscriptional controlling mechanisms could partly explain
the discrepancies between the IHC and SISH results.
Recent studies have demonstrated that HER2 overexpres-
sion indicates a poor prognosis in resected and advanced-stage
NSCLC.24–28 Although some clinical studies have shown prom-
ising results for HER2-targeted therapy in patients with
NSCLC,29–33 other studies have failed to detect a significant
correlation between its expression and DSS in NSCLC.34–36
In a phase II study evaluating a combination of carbo-
platin, paclitaxel, and trastuzumab in 139 patients with ad-
vanced NSCLC, Langer et al.37 reported a potential benefit
for patients with high immunohistochemical HER2 expres-
sion, but the overall survival was similar to historical data
using carboplatin and paclitaxel alone. In another phase II
trial in 103 patients with NSCLC, Gatzemeier et al.38 reported
a possible benefit of trastuzumab therapy for immunohisto-
chemical HER2 3/fluorescence in situ hybridization-posi-
tive patients with NSCLC. Unfortunately, this subgroup was
too small to provide definitive information. Meanwhile, Krug
et al.,39 in a phase II study, observed a better survival after
trastuzumab combined with chemotherapy in 64 patients with
NSCLC. Because of the low frequency of HER2 overexpres-
sion and conflicting results in other trastuzumab combination
studies, the regimen tested was not advanced to phase III.
A common feature of the former clinical trials dealing
with trastuzumab therapy in patients with NSCLC is that the
subgroup of patients included with high HER2 expression
was rather small, which may explain the absence of survival
effect for the whole study population. In a case report from
the study by Cappuzzo et al.,40 a significantly better survival
after trastuzumab treatment was observed in a 60-year-old
female patient with advanced primary adenocarcinoma of the
lung showing high HER2 gene copy number, investigated by
fluorescence in situ hybridization.
By using mRNA expression values, Vallbohmer et al.41
found, in 90 patients with NSCLC, HER2 to be a substantial
gender-specific negative prognostic factor for women, but not
for men. In a recent study, Raso et al.42 demonstrated that
sex-related hormone expression correlated with worse recur-
rence-free survival and with more frequent EGFR mutations.
Several studies have investigated gender as a prognostic
factor,43–45 but studies investigating the gender-specific prog-
nostic or predictive significance of Erb family members in
NSCLC are still rare. Gender differences in cancer tumori-
genesis and survival are most likely related to different sex
hormone effects on various genes.46–48 As the molecular
mechanisms by which HER2 displays prognostic sex speci-
ficity remain to be elucidated, specific assessments should be
included in future trastuzumab studies in NSCLC.
The high number of HER2 gene copies can result from
gene amplification, but a balanced increase in both HER2
gene copies and chromosome 17 copies was observed. The
clinical implication of such a balanced increase has not been
previously investigated. To exclude the possibility that the
increase in the HER2 copy number was a direct result of high
DNA synthesis in proliferating neoplastic cells, we sought to
determine the correlation between HER2 gene copy number
and the protein expression of the proliferation marker Ki67
(Mib1), which is expressed during all proliferative cell-cycle
phases (G1, S, G2, and mitosis) but is absent in resting cells
(G0). These investigations are ongoing (unpublished data),
but apparently there is no significant correlation between
HER2 gene copy number and cell proliferation, contradicting
the hypothesis that increased HER2 gene copy number is a
result of high DNA synthesis in proliferating cells. Our group
is not the first to describe a significant correlation between
high gene copy number and survival; Pauletti et al.49 found
that the maximum number of HER2 gene copies in breast
cancer cells correlated with inferior prognosis.
Our current gender-related prognostic findings as de-
tected by SISH are of high clinical relevance, particularly
when considered alongside clinical trials confirming that
benefits from adjuvant trastuzumab therapy are not confined
to cancer patients with high HER2 expression as detected by
IHC.50 As an analytical method, SISH may be applied in
almost all medical institutions that use IHC. In NSCLC, SISH
seems superior to IHC in predicting prognosis and probably
response to trastuzumab therapy.51 These data show that the
prognostic relevance depicted by SISH is limited to females,
who still accounts for the minority of NSCLC cases, but their
incidence is rapidly increasing.
Based on the data presented herein, the SISH technique
is proposed to be an accurate, practical, and reliable method
for selecting patients for HER2-targeted therapy benefits.
However, future translational prospective studies will be
needed to confirm these results.
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